Xenitra: Half Yearly Report and Accounts
Filed with ASX · · 22 pages · English
Earlier from Xenitra
- EZZ: EZZ Appoints Aumake in $10m Exclusive Dist Agreement
- $10m Exclusive Dist Agreement with EZZ Life Sciences
- Quarterly Activities/Appendix 4C Cash Flow Report
- Aumake Enters High-Growth China OTC Medicine Market
- $1.5m Raised to Support Business Growth
Later from Xenitra
- $30m Danone - Rockcheck Strategic Partnership
- OPAL Token & Xen Shop Launch - Next-Gen Digital Commerce
- Acquisition of Fukang OTC Pharmacy
- Q3 Sales rise by over 305% to $8.3m
- OPAL token launch of EZZ products sells $100k in first week
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra